Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [06/08/2026 11:07 PDT] Aardvark Therapeutics, Inc. (NASDAQ:AARD), Down By 100% ($4.37) From $4.37 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [05/20/2026 07:21 PDT] AARD Expected to Trade Down After Bearish Patterns Develop
• [05/15/2026 21:22 PDT] Market Maker Surveillance Report. AARD, Losing Stocks With Lowest Price Friction For Friday, May 15th 2026
• [05/15/2026 10:29 PDT] Aardvark Therapeutics, Inc. (NASDAQ:AARD), Down By 100% ($5.39) From $5.39 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [05/14/2026 21:21 PDT] Market Maker Surveillance Report. AARD, Losing Stocks With Lowest Price Friction For Thursday, May 14th 2026
• [05/11/2026 07:04 PDT] AARD Expected to Trade Down After Bearish Patterns Develop
• [05/08/2026 07:10 PDT] AARD Expected to Trade Up After Bullish Patterns Develop
• [04/16/2026 07:40 PDT] AARD Expected to Trade Up After Bullish Patterns Develop